New Parkinson's Drug Comes to Market after Early Investment from The Michael J. Fox F
 

New Parkinson's Drug Comes to Market after Early Investment from The Michael J. Fox Foundation

New Parkinson's Drug Comes to Market after Early Investment from The Michael J. Fox Foundation | Parkinson's Disease

making health care affordable to all
 

"we held a meeting with payers (e.g., Medicare/Medicaid and insurance companies) to discuss the impact of Parkinson's symptoms, including "off" episodes. That knowledge may impact decisions on medication coverage"
Imagine if they would make this available at a price affordable to the masses - they would have to "give" up their monopoly on it-make manufacture available to generic manufacturers? For those of us who can't afford any type of insurance but don't fit into medicare or medicaid brackets either....It would be a master play of the big players -change of the guard....using the current system in a new way--levadopa is an old already discovered drug-but dosage and how it is delivered finnesses its application and VALUE.. We already have so many "cures" - not that finding new ones isn't valuable too...its just that there is something to be said for the simple things in life that we take for granted. Sometimes the way out is through. What with depression amongst our youth and 5G EMF signalling massive dopamine depletion the balancing potential in this appears .....mind boggling- sigh

Why is this an application specific to "off" episodes only?

i'm glad this has come to market, it's been approved via clinical trial testing but imho neuros aren't going to write a lot rx's until more patients use it and prove it is really safe and effective and which patients would benefit. i imagine it can get tricky figuring out the dose and timing when you are taking both an inhaled and an oral c/l, which i think will make neuros double cautious for whom they write rx's for and limiting how many inhalers a patient can get. i assume the company wants to start slow to be safe. or maybe not. the mfg wanted to get this to market asap since there is a competing product, sublingual apomorphine, almost approved. apomorphine has been used since the 1970's and was approved in the U.S. as an injectable rescue drug in 2004.

what worries me more is that it appears there is no domestic manufacturer of carbidopa or levodopa and certainly none making C/L tablets. there has been almost a 3 month unavailability of mylan's 50/200ER tablets and shortages of this product from 2 other generic mfgs, i had to switch to SUN's generic and it's not as effective as the MYLAN at least for me. The fact that MYLAN'S regular 25/100 C/L tablet is available implies some other ingredient besides carbidopa and levodopa used to make the ER might only have 1 manufacturer. this seems to be a very fragile supply chain that will be even more succeptible to being interrupted by climate change such as the hurricane that struck peurto rico and damaged some drug plants there.